Aisthesis Medical Limited.

Aisthesis Medical Limited, based in Chester, UK, specializes in enhancing acute care through its innovative VIOSync platform, which leverages advanced data analytics and artificial intelligence to improve patient outcomes in critical conditions. Founded in 2022, Aisthesis Medical Limited focuses on developing technologies for acute care, particularly in sepsis prediction. The company raised EUR 900,000 in Pre-Seed funding on October 1, 2025, led by Twin Path Ventures along with participation from Anglia Capital Group, Cambridge Angels Group, and Martlet Capital. This marks a significant investment target aimed at supporting their growth in the healthcare sector.

Aisthesis Medical's primary offering is the VIOSync platform, designed to enhance acute care through advanced data analytics and artificial intelligence. This product focuses on critical conditions, particularly sepsis prediction, facilitating timely and informed clinical decisions that improve patient outcomes. By optimizing patient journeys from admission through treatment to discharge, VIOSync addresses significant challenges faced by healthcare providers in managing life-threatening conditions. The platform is utilized by hospitals and healthcare systems, targeting markets that prioritize acute care solutions, including North America and Europe.

Aisthesis Medical aims to serve a diverse client base ranging from healthcare providers to hospital administrators, ensuring that their solutions translate into measurable clinical and financial benefits. Aisthesis Medical's revenue model is structured around the deployment of its VIOSync platform, which involves subscription-based contracts with healthcare facilities. This model allows clients to access the platform's predictive analytics and decision-support tools, which are crucial for combating sepsis and enhancing overall patient care. Revenue is generated through direct partnerships with hospitals and healthcare organizations, facilitating a B2B transaction structure.

Specific pricing plans for the services provided by Aisthesis Medical are tailored to the needs of individual healthcare providers, aligning with the scale and scope of their operations. The company continues to explore opportunities for growth, including collaborations and grants, which further support the development and distribution of its flagship products. In October 2025, Aisthesis Medical Limited raised EUR 900,000 in Pre-Seed funding to accelerate the development of its AI-powered clinical decision-support platform and to expand its presence in acute care settings. The company is focusing on enhancing the capabilities of the VIOSync platform and aims to enter new markets across North America and Europe, targeting healthcare providers and hospitals by 2026.

The recent funding will be instrumental in supporting these growth initiatives.